Univariate hazards for transplantation outcomes in patients with AML, according to different KIR-based donor grouping tools
| . | . | n . | Survival . | P . | EFS . | P . | Relapse . | P . | Treatment-related mortality . | P . | Acute GVHD (100 d) . | P . |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| KIR3DL1 Inhibition | ||||||||||||
| KIR3DL1-Weak Inhibiting | 46 | Reference | Reference | Reference | Reference | Reference | ||||||
| KIR3DL1-Noninteracting | 92 | 1.84 (0.98-3.43) | .058 | 2.16 (1.21-3.84) | .009 | 3.03 (1.41-6.5) | .004 | 1.13 (0.44-2.88) | .795 | 1.17 (0.65-2.11) | .604 | |
| KIR3DL1-Strong Inhibiting | 39 | 1.55 (0.76-3.16) | .231 | 1.81 (0.94-3.49) | .077 | 1.98 (0.82-4.79) | .128 | 1.63 (0.61-4.38) | .334 | 1.58 (0.81-3.07) | .18 | |
| KIR3DL1, 2 groups | ||||||||||||
| KIR3DL1-Weak Inhibiting | 46 | Reference | Reference | Reference | Reference | Reference | ||||||
| KIR3DL1-Noninteracting or Strong Inhibiting | 131 | 1.74 (0.95-3.17) | .073 | 2.04 (1.17-3.56) | .012 | 2.68 (1.27-5.64) | .01 | 1.3 (0.55-3.07) | .546 | 1.29 (0.74-2.25) | .376 | |
| KIR2DS1 | ||||||||||||
| KIR2DS1-/HLA-C1+ | 126 | Reference | Reference | Reference | Reference | Reference | ||||||
| KIR2DS1+/HLA-C1+ | 108 | 0.85 (0.53-1.36) | .495 | 1.07 (0.7-1.62) | .758 | 1.19 (0.72-1.97) | .506 | 0.85 (0.4-1.8) | .667 | 1.1 (0.69-1.75) | .702 | |
| Centromeric haplotype B content | ||||||||||||
| CenAA | 88 | Reference | Reference | Reference | Reference | Reference | ||||||
| CenAB | 75 | 0.67 (0.41-1.1) | .115 | 0.67 (0.43-1.05) | .078 | 0.66 (0.39-1.14) | .137 | 0.69 (0.32-1.5) | .347 | 0.79 (0.48-1.3) | .354 | |
| CenBB | 14 | 1.07 (0.45-2.53) | .879 | 1.01 (0.46-2.24) | .976 | 1.04 (0.41-2.67) | .931 | 0.94 (0.22-4.14) | .938 | 0.76 (0.3-1.93) | .562 | |
| Combined ranking schemas | ||||||||||||
| KIR advantageous | 87 | Reference | Reference | Reference | Reference | Reference | ||||||
| No ranking | 34 | 1.5 (0.8-2.79) | .206 | 1.23 (0.7-2.17) | .475 | 0.96 (0.47-1.97) | .913 | 2.04 (0.78-5.38) | .148 | 0.61 (0.29-1.28) | .191 | |
| KIR disadvantageous | 56 | 1.33 (0.79-2.24) | .29 | 1.14 (0.71-1.83) | .578 | 0.99 (0.56-1.74) | .965 | 1.61 (0.68-3.79) | .278 | 1.18 (0.71-1.96) | .527 | |
| . | . | n . | Survival . | P . | EFS . | P . | Relapse . | P . | Treatment-related mortality . | P . | Acute GVHD (100 d) . | P . |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| KIR3DL1 Inhibition | ||||||||||||
| KIR3DL1-Weak Inhibiting | 46 | Reference | Reference | Reference | Reference | Reference | ||||||
| KIR3DL1-Noninteracting | 92 | 1.84 (0.98-3.43) | .058 | 2.16 (1.21-3.84) | .009 | 3.03 (1.41-6.5) | .004 | 1.13 (0.44-2.88) | .795 | 1.17 (0.65-2.11) | .604 | |
| KIR3DL1-Strong Inhibiting | 39 | 1.55 (0.76-3.16) | .231 | 1.81 (0.94-3.49) | .077 | 1.98 (0.82-4.79) | .128 | 1.63 (0.61-4.38) | .334 | 1.58 (0.81-3.07) | .18 | |
| KIR3DL1, 2 groups | ||||||||||||
| KIR3DL1-Weak Inhibiting | 46 | Reference | Reference | Reference | Reference | Reference | ||||||
| KIR3DL1-Noninteracting or Strong Inhibiting | 131 | 1.74 (0.95-3.17) | .073 | 2.04 (1.17-3.56) | .012 | 2.68 (1.27-5.64) | .01 | 1.3 (0.55-3.07) | .546 | 1.29 (0.74-2.25) | .376 | |
| KIR2DS1 | ||||||||||||
| KIR2DS1-/HLA-C1+ | 126 | Reference | Reference | Reference | Reference | Reference | ||||||
| KIR2DS1+/HLA-C1+ | 108 | 0.85 (0.53-1.36) | .495 | 1.07 (0.7-1.62) | .758 | 1.19 (0.72-1.97) | .506 | 0.85 (0.4-1.8) | .667 | 1.1 (0.69-1.75) | .702 | |
| Centromeric haplotype B content | ||||||||||||
| CenAA | 88 | Reference | Reference | Reference | Reference | Reference | ||||||
| CenAB | 75 | 0.67 (0.41-1.1) | .115 | 0.67 (0.43-1.05) | .078 | 0.66 (0.39-1.14) | .137 | 0.69 (0.32-1.5) | .347 | 0.79 (0.48-1.3) | .354 | |
| CenBB | 14 | 1.07 (0.45-2.53) | .879 | 1.01 (0.46-2.24) | .976 | 1.04 (0.41-2.67) | .931 | 0.94 (0.22-4.14) | .938 | 0.76 (0.3-1.93) | .562 | |
| Combined ranking schemas | ||||||||||||
| KIR advantageous | 87 | Reference | Reference | Reference | Reference | Reference | ||||||
| No ranking | 34 | 1.5 (0.8-2.79) | .206 | 1.23 (0.7-2.17) | .475 | 0.96 (0.47-1.97) | .913 | 2.04 (0.78-5.38) | .148 | 0.61 (0.29-1.28) | .191 | |
| KIR disadvantageous | 56 | 1.33 (0.79-2.24) | .29 | 1.14 (0.71-1.83) | .578 | 0.99 (0.56-1.74) | .965 | 1.61 (0.68-3.79) | .278 | 1.18 (0.71-1.96) | .527 | |